BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Preclinical and early-phase clinical data suggest that immune modulation represents a
treatment strategy that is worthy of further investigation in relapsed epithelial ovarian
cancer. One method by which tumor cells may evade immune surveillance is by activation of the
programmed cell death (PD-1) pathway, mediated by expression of PD-1 on the surface of T
lymphocytes, which conveys an inhibitory signal after binding to its ligand PD-L1 on the
surface of tumor cells. Nivolumab and Ipilimumab have shown activity as monotherapies in
solid tumors and very early data suggest that nivolumab may be particularly active for
ovarian clear cell carcinoma.(Hamanishi et al., 2015). Given the uniformly poor prognosis for
patients with clear cell carcinoma in general, we are interested in formally evaluating this
agent in all extra-renal clear cell carcinomas.
Phase:
Phase 2
Details
Lead Sponsor:
Don Dizon
Collaborators:
Bristol-Myers Squibb Brown University Brown University Oncology Research Group Rhode Island Hospital The Miriam Hospital Women and Infants Hospital of Rhode Island